Worth reading
49Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Definitive
How definitive the wording is.Who is moving to which position
Resolved 26 August 2026Incoming appointee
5 itemsScheduled Appointment DateEffective 1 September 2026
Imai Masaya (今井 昌也)
Previous positionExecutive Officer, Iga-Shiga Group Head
New positionSenior Executive Officer, Iga-Shiga Group Head
Yoshizawa Yuko (吉澤 優子)
Previous positionManager, Administration Department, Eastern Headquarters
New positionManager, Administration Department, Eastern Headquarters
Toyama Kunihiko (遠山 邦彦)
Previous positionNot disclosed
New positionRepresentative Director and President (株式会社ヘルシー薬局)
Fujita Kazushi (藤田 和司)
Previous positionRepresentative Director (株式会社京寿薬品)
New positionRepresentative Director and President (株式会社京寿薬品)
Furuichi Kazuhisa (古市 和久)
Previous positionNot disclosed
New positionDirector (株式会社京寿薬品)
Departing officer
2 itemsDate of departure31 August 2026 (Matsumoto Takefumi (松本 剛文), Adachi Yoshiyuki (安達 佳之))
Matsumoto Takefumi (松本 剛文)Stepping down
Former PositionSenior Executive Officer, Manager of the Administration Department, Eastern Headquarters
Adachi Yoshiyuki (安達 佳之)Stepping down
Former PositionRepresentative Director and President
Whether the incumbent will remain in office (whether they will retain their position)
No statement that the individual will remain on the board
Directors after the change5Number
| Item | Details |
|---|---|
| Resolution date | 26 August 2026 |
| Scheduled Appointment Date | Effective 1 September 2026 |
| Date of departure | 31 August 2026 (Matsumoto Takefumi (松本 剛文), Adachi Yoshiyuki (安達 佳之)) |
| Name of appointee | Imai Masaya (今井 昌也), Yoshizawa Yuko (吉澤 優子), Toyama Kunihiko (遠山 邦彦), Fujita Kazushi (藤田 和司), Furuichi Kazuhisa (古市 和久) |
| Appointee's new position | Senior Executive Officer, Iga-Shiga Group Head, Manager, Administration Department, Eastern Headquarters, Representative Director and President (株式会社ヘルシー薬局), Representative Director and President (株式会社京寿薬品), Director (株式会社京寿薬品) |
| Appointee's previous position | Executive Officer, Iga-Shiga Group Head, Manager, Administration Department, Eastern Headquarters, Not disclosed, Representative Director (株式会社京寿薬品), Not disclosed |
| Name of departing officer | Matsumoto Takefumi (松本 剛文), Adachi Yoshiyuki (安達 佳之) |
| Former position of departing officer | Senior Executive Officer, Manager of the Administration Department, Eastern Headquarters, Representative Director and President |
| Whether the incumbent will remain in office | No statement that the individual will remain on the board |
| Number of directors after the change | メディカル一光: 5 directors (including 2 outside directors); ヘルシー薬局: 4 directors (including 0 outside directors); 京寿薬品: 3 directors (including 0 outside directors) |
Items this document does not state (11)
Appointee's date of birthYear the appointee joined the CompanyNumber of shares held by the appointeeNew position of departing officerReason for departureReason for changeReasons for appointmentFiling as an independent officerDetails of organizational changesChange in Corporate Governance StructureSubject to Approval by the General Meeting of Shareholders
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company states that it decided to make the personnel changes, but does not provide specific reasons for the changes or the retirements.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.